datetime,headline,summary,related,lang,source
2020-12-01 08:30:00-05:00,Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC). Zymeworks will receive a US$10 million payment under its collaboration with BeiG",ZYME,en,Business Wire
2020-11-19 15:04:00-05:00,"Zymeworks erhält Orphan-Drug-Status von der Europäischen Kommission für den gegen HER2 gerichteten, bispezifischen Antikörper Zanidatamab bei Patienten mit Magenkrebs","VANCOUVER, British Columbia--(BUSINESS WIRE)--Wie Zymeworks Inc. (NYSE:ZYME), ein biopharmazeutisches Unternehmen, das multifunktionale Biotherapeutika in der klinischen Phase entwickelt, heute bekannt gab, hat die Europäische Kommission den Orphan-Drug-Status für Zanidatamab erteilt. Dabei handelt es sich um einen von dem Unternehmen entwickelten, gegen HER2 gerichteten bispezifischen Antikörper, der bei Patienten mit Magenkrebs erprobt wird. „Die Bestätigung des Nutzens von Zanidatamab bei de",ZYME,de,Business Wire
2020-11-19 08:30:00-05:00,Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer. “We are encouraged by the European Commission’s and European Medicines Agency’s recognition of the benefit that zanidatamab can provide i",ZYME,en,Business Wire
2020-11-16 16:15:00-05:00,Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NA",ZYME,en,Business Wire
2020-11-04 07:35:18-05:00,Raymond James Stick to Their Buy Rating for Zymeworks Inc,Raymond James Stick to Their Buy Rating for Zymeworks Inc,ZYME,en,Investing.com
2020-11-03 16:15:00-05:00,Zymeworks Reports 2020 Third Quarter Financial Results,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended September 30, 2020. “Zanidatamab’s clinical development continued to expand this quarter, having opened new sites across the globe for the pivotal trial in HER2-amplified biliary tract cancers toward our first potential BLA submission,” said Ali Tehrani, Ph.D., Zymeworks’ President",ZYME,en,Business Wire
2020-11-03 10:19:00-05:00,"Zymeworks , Will stock surge before Earnings results? Stock market Insights & financial analysis","Zymeworks announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…",ZYME,en,Stock Market Daily
2020-10-21 23:40:48-05:00,Zymeworks Inc. (NYSE:ZYME) Sees Significant Decline in Short Interest,"Zymeworks Inc. (NYSE:ZYME) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,980,000 shares, a decrease of 12.8% from the September 15th total of 2,270,000 shares. Approximately 5.1% of the shares of the company are sold short. Based on an […]",ZYME,en,The Lincolnian
2020-10-21 06:44:55-05:00,Zymeworks Inc. (NYSE:ZYME) Short Interest Down 12.8% in September,"Zymeworks Inc. (NYSE:ZYME) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 1,980,000 shares, a decrease of 12.8% from the September 15th total of 2,270,000 shares. Based on an average daily volume of 458,300 shares, the short-interest ratio is currently 4.3 days. Approximately […]",ZYME,en,Stock Observer
2020-10-21 04:40:45-05:00,Zymeworks Target of Unusually Large Options Trading (NYSE:ZYME),"Zymeworks Inc. (NYSE:ZYME) was the recipient of unusually large options trading on Monday. Traders acquired 1,032 put options on the stock. This represents an increase of 1,811% compared to the typical daily volume of 54 put options. Zymeworks stock opened at $43.27 on Wednesday. Zymeworks has a 12 month low of $20.33 and a 12 […]",ZYME,en, Dakota Financial News
2020-10-20 11:44:51-05:00,Zymeworks Sees Unusually High Options Volume (NYSE:ZYME),"Zymeworks Inc. (NYSE:ZYME) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 1,032 put options on the company. This is an increase of approximately 1,811% compared to the average volume of 54 put options. NYSE:ZYME traded down $0.75 during midday trading on Tuesday, hitting $44.60. 4,853 shares of the stock […]",ZYME,en,Transcript Daily
2020-10-20 06:36:47-05:00,Zymeworks Inc. (NYSE:ZYME) Sees Large Decrease in Short Interest,"Zymeworks Inc. (NYSE:ZYME) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,980,000 shares, a drop of 12.8% from the September 15th total of 2,270,000 shares. Based on an average daily trading volume, of 458,300 shares, the short-interest ratio is presently 4.3 days. […]",ZYME,en,Zolmax News
2020-09-11 10:05:52-05:00,"Checkpoint Therapeutics, Nano-X Imaging leads healthcare gainers, Evofem Biosciences, Satsuma Pharmaceuticals among major losers","Gainers: Checkpoint Therapeutics (NASDAQ:CKPT) +29%, Nano-X Imaging (NASDAQ:NNOX) +21%, Biofrontera AG (NASDAQ:BFRA) +20%, Zymeworks (NYSE:ZYME) +14%, MEI",ZYME,en,Seeking Alpha
2020-09-03 07:30:00-05:00,Zymeworks to Present at Upcoming Investor Conferences,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences. Wells Fargo’s 2020 Healthcare Conference is scheduled for September 9-10, 2020. Zymeworks is presenting on Wednesday, September 9, 2020 at 11:20 a.m. ET. Citi’s 15th Annual BioPharma Conference is scheduled for September 9-10, 2020. H.C. Wa",ZYME,en,Business Wire
2020-08-05 15:15:00-05:00,Zymeworks Reports 2020 Second Quarter Financial Results,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended June 30, 2020. “Among many notable accomplishments in the past quarter, I am particularly excited about the transition of our lead therapeutic program, zanidatamab, into late stage clinical development, providing a clear path for Zymeworks to seek its first potential approval in bi",ZYME,en,Business Wire
2020-07-08 16:30:00-05:00,Zymeworks Corporate Update Webcast and Conference Call Summary,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020. “I’m proud to say we’ve taken a major step towards achieving our goal of bringing an important new therapeutic to patients with HER2-expressing cancers,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks. “ZW25,",ZYME,en,Business Wire
2020-07-08 15:15:00-05:00,Zymeworks Announces New Multispecific Antibody Collaboration with Merck,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longti",ZYME,en,Business Wire
2020-06-30 07:30:00-05:00,Zymeworks Announces Corporate Update Webcast and Conference Call,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a w",ZYME,en,Business Wire
2020-05-28 07:30:00-05:00,Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020. The Company’s presentation will be on Thursday, June 4, 2020 at 2:30 p.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zymeworks.com",ZYME,en,Business Wire
2020-05-07 15:15:00-05:00,Zymeworks Reports 2020 First Quarter Financial Results,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020. “While the COVID-19 pandemic has presented unprecedented global challenges, the entire Zymeworks team remains committed to our mission of returning patients home to their loved ones, disease free,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “The",ZYME,en,Business Wire
2020-05-04 13:00:00-05:00,"Applied BioMath, LLC Announces Collaboration with Zymeworks","CONCORD, Mass., May 4, 2020 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced the continuation of their collaboration…",ZYME,en,PR Newswire
2020-03-02 16:15:00-05:00,Zymeworks Reports 2019 Year-End Financial Results,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019. “We’ve started the year off strong thanks to significant clinical progress in the second half of 2019 and a recent financing that has provided expanded resources to further advance global development of our clinical candidates, ZW25 and ZW49,” said Ali Tehrani, Ph.D",ZYME,en,Business Wire
2020-02-24 08:30:00-05:00,Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March 1-4, 2020 in Orlando, FL. The Company’s presentation will be on Monday, March 2, 2020 at 2:15 p.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http:",ZYME,en,Business Wire
2020-01-23 07:24:36-05:00,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT )(reported strong fourth-quarter results and issued in-line guidance) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) Bristol-Myers Squibb Co (NYSE: BMY ) Cardiovascular Systems Inc (NASDAQ: CSII ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Eli Lilly And Co (NYSE: LLY ) Fortress Biotech (NASDAQ: FBIO ) Horizon Therapeutics PLC (NASDAQ: HZNP )( received FDA nod for its thyroid eye disease drug) Insulet Corporation (NASDAQ: PODD ) Medtronic PLC (NYSE: MDT ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR )(announced coverage in Israel for its Optune in combination with temozolomide for the treatment of newly-diagnosed glioblastoma) Prevail Therapeutics Inc (NASDAQ: PRVL ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. (NYSE: RMD ) Selecta Biosciences Inc (NASDAQ: SELB ) SI-Bone Inc (NASDAQ: SIBN ) Soligenix, Inc.","ZTS,ZYME",en,Benzinga
2020-01-13 08:30:00-05:00,Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2019 and updated its corporate priorities. Zymeworks also announced multiple clinical program advances for its lead candidates, ZW25 and ZW49. Recent ZW25 and ZW49 Program Advances Zymeworks initiated a Phase 2 clinical trial evaluating ZW25 in combination with Ibrance® (palbociclib), an ora",ZYME,en,Business Wire
2020-01-12 10:00:00-05:00,Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib),"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific antibody ZW25 is being evaluated in combination with Pfizer’s Ibrance® (palbociclib), an oral CDK4/6 inhibitor, and the hormone therapy fulvestrant in patients wit",ZYME,en,Business Wire
2020-01-10 07:13:12-05:00,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.","ZTS,ZYME",en,Benzinga
2020-01-07 08:30:00-05:00,Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3:30 p.m. PT. The presentation will be webcast live and available for replay on Zymeworks’ website at ht",ZYME,en,Business Wire
2019-11-22 02:30:00-05:00,Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress,"SINGAPORE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients with HER2‑expressing solid tumors in a mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore. Zymeworks and its collaborator BeiGene, Ltd. pla",ZYME,en,Business Wire
2019-11-18 08:30:00-05:00,Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the selection of an abstract highlighting updated single agent data from the Phase 1 clinical trial evaluating the HER2‑targeted bispecific antibody, ZW25, in patients with HER2‑expressing solid tumors for a mini oral presentation at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore. The presentation,",ZYME,en,Business Wire
2019-11-05 18:00:00-05:00,Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional therapeutics, announced today that it has filed an automatic shelf registration statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) to replace its existing shelf registration statement on Form S-3. Zymeworks has become a “well-known seasoned issuer” (“WKSI”) under SEC rules and is filing the new",ZYME,en,Business Wire
2019-11-04 16:15:00-05:00,Zymeworks to Present at Stifel 2019 Healthcare Conference,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present at the upcoming Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York, NY. The Company’s presentation will be on Tuesday, November 19, 2019 at 8:00 a.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir",ZYME,en,Business Wire
2019-10-29 09:32:42-05:00,Earnings Preview: Zymeworks Inc. (ZYME) Q3 Earnings Expected to Decline,Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ZYME,en,Zacks Investment Research
2019-08-02 17:35:03-05:00,"Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates","Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -10.91% and 8.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?",ZYME,en,Zacks Investment Research
2019-07-31 09:35:59-05:00,Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher?,Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ZYME,en,Zacks Investment Research
2019-05-16 06:27:29-05:00,GSK expands collaboration with Zymeworks,No summary available.,ZYME,en,Seeking Alpha
2019-05-02 16:15:44-05:00,"Zymeworks beats by $0.09, beats on revenue",No summary available.,ZYME,en,Seeking Alpha
2019-04-30 14:52:15-05:00,Zymeworks (ZYME) Presents At Bloom Burton & Co. Healthcare Investor Conference - Slideshow,No summary available.,ZYME,en,Seeking Alpha
2019-04-28 07:00:29-05:00,"Eyes On Apple, Uber, F8 And Avengers (Stocks To Watch Podcast)",No summary available.,"ZNGA,ZYME,ZAYO",en,Seeking Alpha
2019-04-27 08:12:19-05:00,"Stocks To Watch: Eyes On Apple, Uber, F8 And Avengers",No summary available.,"ZNGA,ZYME,ZAYO",en,Seeking Alpha
2019-04-25 06:17:00-05:00,Zymeworks nabs $3.5M milestone from Daiichi on license of cancer candidate,No summary available.,ZYME,en,Seeking Alpha
2019-04-15 07:58:48-05:00,Zymeworks launches mid-stage trial for ZW25,No summary available.,ZYME,en,Seeking Alpha
2019-03-12 14:17:50-05:00,Zymeworks (ZYME) Presents At Barclays Global Healthcare Conference - Slideshow,No summary available.,ZYME,en,Seeking Alpha
2019-03-06 17:17:44-05:00,Zymeworks beats by $0.97,No summary available.,ZYME,en,Seeking Alpha
2019-02-13 16:49:05-05:00,Baker Brothers own 5.3% of Zymeworks,No summary available.,ZYME,en,Seeking Alpha
2019-01-18 06:50:19-05:00,Zymeworks earns $8M milestone from licensee Lilly,No summary available.,ZYME,en,Seeking Alpha
2019-01-18 06:50:19-05:00,Zymeworks earns $8M milestone from licensee Lilly,No summary available.,ZYME,en,Seeking Alpha
